fludarabine has been researched along with Malignant Melanoma in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battiwalla, M; Brazauskas, R; Buchbinder, D; Cahoon, EK; Curtis, RE; Engels, EA; Flowers, ME; Herr, MM; Morton, LM; Shaw, BE; Tecca, HR; Tucker, MA | 1 |
| Asher, N; Ben-Betzalel, G; Ben-Nun, A; Besser, MJ; Brezinger, K; Itzhaki, O; Kubi, A; Levi, M; Markel, G; Nagler, A; Nissani, A; Schachter, J; Shapira-Frommer, R; Shimoni, A; Zeltzer, LA; Zikich, D; Zippel, DB | 1 |
| Asher, N; Ben-Betzalel, G; Besser, MJ; Itzhaki, O; Jacoby, E; Lev-Ari, S; Markel, G; Meirson, T; Nissani, A; Schachter, J; Shapira-Frommer, R | 1 |
| Amagai, M; Fujita, T; Fukuda, K; Funakoshi, T; Handa, M; Hirai, I; Iwata, T; Kamijuku, H; Kato, J; Kawakami, Y; Koda, Y; Mori, M; Mori, T; Noji, S; Ohta, S; Okamoto, S; Sakurai, M; Tanosaki, R; Watanabe, N; Yaguchi, T | 1 |
| Citrin, DE; Rosenberg, SA; Tseng, J; Waldman, M; White, DE; Yang, JC | 1 |
| Citrin, DE; Downey, SG; Dudley, ME; Huang, J; Hughes, MS; Kammula, U; Klapper, J; Laurencot, C; Leitman, SF; Morton, K; Restifo, NP; Robbins, PF; Rosenberg, SA; Royal, R; Sherry, R; Smith, FO; Thomasian, A; White, DE; Wunderlich, J; Yang, JC | 1 |
| Cao, J; Reilly, JZ; Rodmyre, RM; Thompson, JA; Wallen, H; Yee, C | 1 |
| Apter, S; Besser, MJ; Catane, R; Hardan, I; Itzhaki, O; Kubi, A; Kuchuk, I; Markel, G; Nagler, A; Nun, AB; Schachter, J; Schallmach, E; Segal, E; Shalmon, B; Shapira-Frommer, R; Shimoni, A; Treves, AJ; Zippel, D | 1 |
| Bishop, RJ; Caruso, R; Chan, CC; Cunningham, D; Ding, X; Heller, CK; Illei, G; Pavletic, S | 1 |
| Appay, V; Canellini, G; Laurent, J; Leyvraz, S; Papaioannou, A; Rimoldi, D; Romero, P; Rufer, N; Speiser, DE; Touvrey, C; Vicari, M; Voelter, V | 1 |
| Ellwanger, S; Gibney, G; Janssen, W; Kudchadkar, R; Kuhn, L; Marzban, S; Mulé, JJ; Pilon-Thomas, S; Royster, E; Sarnaik, AA; Sondak, VK; Weber, J; Zager, J | 1 |
| Abati, A; Berman, DM; Dudley, ME; Filie, AC; Gea-Banacloche, J; Gracia, GJ; Jones, SA; Kammula, U; Mangiameli, DP; Mavroukakis, SA; Pelletier, MM; Restifo, NP; Robinson, MR; Rogers, LJ; Rosenberg, SA; Royal, RE; Sherry, RM; Topalian, SL; White, DE; Wunderlich, JR; Yang, JC | 1 |
| Denning, MF; Nickoloff, BJ; Qin, JZ; Sitailo, LA; Xin, H | 1 |
| Bosly, A; Brousset, P; Delannoy, A; Pris, J; Riga-Huguet, F; Schlaifer, D | 1 |
| De Marco, C; Gornati, D; Orlandi, L; Silvestrini, R; Vaglini, M; Zaffaroni, N | 1 |
| Da Prada, GA; Della Cuna, GR; Giorgiani, G; Giraldi, E; Landonio, G; Locatelli, F; Pedrazzoli, P; Schiavo, R; Siena, S; Zambelli, A | 1 |
8 trial(s) available for fludarabine and Malignant Melanoma
| Article | Year |
|---|---|
Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
Topics: Administration, Intravenous; Cell Culture Techniques; Cyclophosphamide; Feasibility Studies; Gene Regulatory Networks; Humans; Immune Checkpoint Inhibitors; Immunotherapy, Adoptive; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Pilot Projects; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2021 |
Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy, Adoptive; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Pilot Projects; Radiation Injuries; Recombinant Proteins; Thrombotic Microangiopathies; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Topics: Adolescent; Adoptive Transfer; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Chemotherapy, Adjuvant; Child; Cyclophosphamide; Female; Humans; Interleukin-15; Interleukin-2; Interleukin-7; Kaplan-Meier Estimate; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Myeloablative Agonists; Neoadjuvant Therapy; Neoplasm Metastasis; Pilot Projects; Radiotherapy Dosage; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome; Vidarabine | 2008 |
Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cytokines; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Forkhead Transcription Factors; Humans; Immunotherapy, Adoptive; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome; Vidarabine | 2009 |
Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Topics: Acyclovir; Adult; Aged; Antifungal Agents; Antineoplastic Agents, Alkylating; Antiviral Agents; Cyclophosphamide; Cytotoxicity, Immunologic; Female; Fluconazole; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy, Adoptive; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Skin Neoplasms; Vidarabine | 2009 |
Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.
Topics: Aged; Busulfan; Cancer Vaccines; CD8 Antigens; Cell Proliferation; Cyclophosphamide; Cytokines; Female; Freund's Adjuvant; Humans; Immunotherapy, Adoptive; Lymphocyte Depletion; Male; MART-1 Antigen; Melanoma; Middle Aged; Peptide Fragments; Skin Neoplasms; T-Lymphocytes; Vidarabine | 2010 |
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.
Topics: Adult; Aged; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Lymphopenia; Male; Melanoma; Middle Aged; Pilot Projects; Skin Neoplasms; Treatment Outcome; Tumor Cells, Cultured; Vidarabine | 2012 |
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Topics: Adolescent; Adoptive Transfer; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Treatment Outcome; Vidarabine | 2005 |
8 other study(ies) available for fludarabine and Malignant Melanoma
| Article | Year |
|---|---|
Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Busulfan; Case-Control Studies; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Karnofsky Performance Status; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Staging; Risk Factors; Skin; Skin Neoplasms; Tissue Donors; Transplantation Conditioning; Ultraviolet Rays; Vidarabine; Whole-Body Irradiation; Young Adult | 2020 |
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response.
Topics: Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cyclophosphamide; Female; Follow-Up Studies; Humans; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Prognosis; Progression-Free Survival; Skin Neoplasms; Vidarabine | 2020 |
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.
Topics: Adult; Clinical Trials, Phase II as Topic; Cyclophosphamide; Cytokines; Female; Humans; Immunotherapy, Adoptive; Length of Stay; Lymphocyte Depletion; Male; Melanoma; Middle Aged; Myeloablative Agonists; Receptors, Chimeric Antigen; Recovery of Function; Skin Neoplasms; T-Lymphocytes; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2021 |
Rapid vision loss associated with fludarabine administration.
Topics: Antineoplastic Agents; Blindness; Brain Diseases; Electroretinography; Evoked Potentials, Visual; Fatal Outcome; Female; Humans; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Myeloablative Agonists; Retina; Retinal Diseases; Retrospective Studies; Vidarabine; Young Adult | 2010 |
Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Melanoma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protease Inhibitors; Protein Interaction Mapping; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Ultraviolet Rays; Vidarabine | 2006 |
Secondary neoplasms in two patients treated with purine analogues.
Topics: Acute Disease; Aged; Cladribine; Female; Humans; Immunocompromised Host; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melanoma; Neoplasms, Second Primary; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines.
Topics: Antineoplastic Agents; Cisplatin; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Melanoma; Ovarian Neoplasms; Tumor Cells, Cultured; Vidarabine | 1996 |
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Renal Cell; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Pilot Projects; Sarcoma; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |